lunes, 28 de septiembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 27, 2025

Human Growth Hormone Injection Market Size Expected to Reach USD 8.54 Bn by 2035

View original at globenewswire.com
Human Growth Hormone Injection Market Size Expected to Reach USD 8.54 Bn by 2035 Ottawa, Nov…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • In-house manufacturing segment was dominant in the human growth hormone injection market in 2024, with a 70% share

    80% confidence

  • The global human growth hormone injection market size is calculated at USD 4.82 billion in 2026 and is expected to reach around USD 8.54 billion by 2035, growing at a CAGR of 6.55%

    80% confidence

  • Novo Nordisk spent nearly $6.3 billion last year to bolster its manufacturing capabilities

    80% confidence

  • Branded HGH injections segment held the largest market revenue of 65% in 2024

    80% confidence

  • Novo Nordisk spent approximately $9 billion in 2025 to create additional capacity across the supply chain

    80% confidence

  • Subcutaneous injection segment was dominant in the market in 2024, with a 90% share

    80% confidence

  • Hospital pharmacies segment was dominant in the market in 2024, with a 45% share

    80% confidence

  • Online pharmacies segment is expected to register the fastest growth over the forecast period, 2025 to 2034

    80% confidence

  • Outsourced manufacturing segment is expected to register the fastest growth over the forecast period, 2025 to 2034

    80% confidence

  • Metabolic disorders segment is expected to register the fastest growth over the forecast period, 2025 to 2034

    80% confidence

  • Asia Pacific is expected to be the fastest-growing region over the forecast period, 2025 to 2034

    80% confidence

  • Pfizer's Somatropin-LA shows promising Phase 3 results for pediatric growth hormone deficiency with improved weekly dosing benefits

    80% confidence

  • Generic HGH injections segment is the fastest-growing over the forecast period, 2025 to 2034

    80% confidence

  • Pediatric growth disorders segment was dominant in the human growth hormone injection market in 2024, with a 40% share

    80% confidence

  • North America was dominant in the human growth hormone injection Market, with a 55% share

    80% confidence

  • Recombinant DNA (rDNA) HGH segment was dominant in the market revenue in 2024, with an 85% share

    80% confidence

Data points we hold from this source

Novo Nordisk A/S · capex9 billion_USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,984
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,984 hechos verificados con la fuente5,306 documentos fuente archivados
Consulta estos datos → isubstrate.com
Human Growth Hormone Injection Market Size Expected to Reach USD 8.54 Bn by 2035 — Source | Via News | es.VIA.NEWS